Qinlock Side Effects

Generic name: ripretinib

Medically reviewed by Drugs.com. Last updated on Mar 31, 2024.

Note: This document contains side effect information about ripretinib. Some dosage forms listed on this page may not apply to the brand name Qinlock.

Applies to ripretinib: oral tablet.

Serious side effects of Qinlock

Along with its needed effects, ripretinib (the active ingredient contained in Qinlock) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking ripretinib:

More common

Blistering, peeling, loosening of the skin
bloating or swelling of the face, arms, hands, lower legs, or feet
blurred vision
chest tightness
constipation
diarrhea
difficult or labored breathing
dizziness
headache
nausea or vomiting
nervousness
pounding in the ears
rash, redness, swelling, pain, or ulceration of the skin
scaling of the skin on the hands and feet
slow or fast heartbeat
stomach pain
tingling of the hands or feet
unusual weight gain or loss

Less common

Change in size, shape, or color of existing mole
chest pain or discomfort
decreased urine output
dilated neck veins
irregular breathing
irregular heartbeat
mole that leaks fluid or bleeds
new mole
pale skin
trouble breathing
unusual bleeding or bruising
unusual tiredness or weakness

Rare

Increased sensitivity of the skin to sunlight
redness or other discoloration of the skin
severe sunburn

Other side effects of Qinlock

Some side effects of ripretinib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Difficulty in moving
dry or itching skin
joint pain or swelling
lack or loss of strength
loss of appetite
loss or thinning of the hair
muscle pains or stiffness
swelling or inflammation of the mouth

For Healthcare Professionals

Applies to ripretinib: oral tablet.

General

The most common adverse reactions are alopecia, fatigue, nausea, abdominal pain, constipation, myalgia, diarrhea, decreased appetite, palmar-plantar erythrodysesthesia syndrome (PPES), and vomiting.^[Ref]

Cardiovascular

Very common (10% or more): Hypertension (up to 19.4%)

Common (1% to 10%): Cardiac dysfunction (e.g., cardiac failure, acute left ventricular failure, diastolic dysfunction, ventricular hypertrophy), cardiac ischemic events (including acute coronary syndrome and fatal cardiac arrest or myocardial infarction)^[Ref]

Dermatologic

Very common (10% or more): Alopecia (up to 52%), palmar-plantar erythrodysesthesia syndrome (PPES) (up to 29.8%), dry skin (up to 17%), pruritus (11%)

Common (1% to 10%): Photosensitivity

Frequency not reported: Dermatosis^[Ref]

Gastrointestinal

Very common (10% or more): Nausea (39%), abdominal pain (36%), constipation (34%), lipase increased (32%), diarrhea (28%), vomiting (21%), serum amylase increased (13%), stomatitis (11%)^[Ref]

Hematologic

Common (1% to 10%): Anemia (3.5%)^[Ref]

Hepatic

Very common (10% or more): Increased bilirubin (22%), increased alanine aminotransferase (ALT) (12%)^[Ref]

Metabolic

Very common (10% or more): Decreased appetite (27%)^[Ref]

Musculoskeletal

Very common (10% or more): Myalgia (up to 37.8%), arthralgia (up to 21.2%), muscle spasms (15%)

Frequency not reported: Arthritis^[Ref]

Nervous system

Very common (10% or more): Headache (up to 20.7%)

Frequency not reported: Hyperesthesia^[Ref]

Oncologic

Common (1% to 10%): Cutaneous squamous cell carcinoma, keratoacanthoma, melanoma^[Ref]

Other

Very common (10% or more): Fatigue (up to 51%), increased creatine phosphokinase (CPK) (21%), peripheral edema (up to 17%), asthenia (13%), increased triglycerides (26%), decreased phosphate (26%), decreased calcium (23%), weight loss (up to 26.5%), decreased sodium (17%), increased activated partial thromboplastin time (35%), increased international normalized ration (INR) (21%), decreased neutrophil count (10%), increased lipase (up to 32%), increased serum amylase (13%)

Common (1% to 10%): Physical health deterioration^[Ref]